ANN ARBOR, Mich., Oct. 12 /PRNewswire/ — Adeona
Pharmaceuticals, Inc., (Amex:
AEN) announced five scientific publications on the role of
copper toxicity and zinc deficiency in Alzheimer’s disease and
cognitive decline. The author of all these publications is Adeona’s
scientific founder and consultant, George J. Brewer, M.D., the
Morton S. and Henrietta Sellner Emeritus Professor of Human
Genetics and Internal Medicine at the University of Michigan.
The first two publications describe the results of Adeona’s
observational clinical study of zinc and copper status in 29
patients with Alzheimer’s disease, 30 patients with Parkinson’s
disease, and 29 age- and sex-matched controls (CopperProof-1). The
CopperProof-1 study was conducted at Albany Medical Center by Earl
Zimmerman, M.D., Director of the Alzheimer’s Centers, Eric Molho,
M.D., Director of the Parkinson’s Disease Centers and Dzintra
Celmins, M.D., of the Parkinson’s Disease Centers.
The first publication entitled, “Subclinical Zinc Deficiency in
Alzheimer’s Disease and Parkinson’s Disease,” was published in the
November 2010 issue of the American Journal of Alzheimer’s
Disease & Other Dementias. Serum zinc and urinary zinc were
compared across the three groups of patients. The results showed a
significantly lower serum zinc level in patients with Alzheimer’s
and patients with Parkinson’s than in controls.
The second publication entitled, “Copper and Ceruloplasmin
Abnormalities in Alzheimer’s Disease,” was published in the
September 2010 issue of the American Journal of Alzheimer’s
Disease and Other Dementias. That publication describes how
copper may play a role in the pathogenesis of Alzheimer’s disease
and increased exposure to environmental copper and/or defective
ceruloplasmin function could directly be contributing to the
Alzheimer’s epidemic.
Since the initial presenta
‘/>”/>
SOURCE